At1g25270 Antibody
Description
Gene Context of At1g25270
-
Locus: At1g25270 is annotated in the Arabidopsis genome as a gene encoding a DUF1639 domain-containing protein with unknown molecular function[^1].
-
Expression: Limited expression data suggest it may play roles in stress responses or developmental processes, but no experimental validation exists[^2].
-
Homology: No direct orthologs in mammalian systems have been identified, narrowing its relevance to plant-specific research.
Antibody Development Challenges
-
Commercial Availability: No commercial or custom antibodies targeting At1g25270 are listed in major antibody repositories (e.g., Thermo Fisher, Abcam, or Sigma-Aldrich catalogs).
-
Research Gap: No publications in PubMed, PMC, or Google Scholar describe the generation or use of At1g25270-specific antibodies, indicating a lack of demand or technical hurdles (e.g., low immunogenicity of the target protein).
Related Antibody Technologies
While At1g25270 antibodies are unavailable, the search results highlight advanced methodologies for antibody development that could theoretically apply:
| Technology | Relevance to At1g25270 Research |
|---|---|
| Monoclonal Antibody Engineering | Used for targeting GPCRs (e.g., AT1R)[^3][^5] and viral proteins[^7][^11]. |
| Nanobody Design | Enables high specificity for low-abundance targets[^5]. |
| ELISA/Immunoassays | Standard tools for validating antibody-antigen interactions[^3][^4]. |
Potential Research Directions
-
Immunogen Design: Synthesize peptides from conserved regions of the At1g25270 protein sequence to raise polyclonal antibodies.
-
Functional Studies: Use CRISPR-edited Arabidopsis lines to study phenotypic changes and infer protein function.
-
Collaborative Efforts: Partner with plant biology consortia (e.g., TAIR or ABRC) to prioritize antibody development for uncharacterized genes.
Key Limitations
-
Absence of Cross-Reactivity Data: Antibodies against plant proteins like At1g25270 are unlikely to cross-react with human/mammalian proteins due to evolutionary divergence.
-
Funding Priorities: Most antibody research focuses on clinically relevant targets (e.g., AT1R in hypertension[^2][^4] or SARS-CoV-2 spike proteins[^6][^10]).
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Here’s a curated collection of FAQs tailored to academic research scenarios for the At1g25270 Antibody, synthesized from peer-reviewed methodologies and validation frameworks:
How can I validate the specificity of an At1g25270 antibody in Western blot (WB)?
Methodological Answer:
-
Knockout (KO) Validation: Use isogenic wild-type (WT) and CRISPR-generated KO cell lines for the target protein. Compare band patterns between WT and KO lysates. A specific antibody will show a band in WT but not KO lysates .
-
Orthogonal Controls: Pair WB with immunoprecipitation (IP) using the same antibody. Confirm co-precipitation of the target via mass spectrometry or a secondary orthogonal antibody .
-
Application-Specific Buffers: Optimize lysis buffer composition (e.g., RIPA vs. NP-40) to prevent epitope masking .
Example Validation Data:
| Assay | WT Signal | KO Signal | Specificity Score |
|---|---|---|---|
| WB | Strong | Absent | High |
| IP | Enriched | No pull-down | Confirmed |
What experimental controls are critical for immunofluorescence (IF) studies with this antibody?
Methodological Answer:
-
Isotype Controls: Use same-host species IgG under identical staining conditions to rule out non-specific binding .
-
KO Tissue Sections: Include tissue/cells from KO models to confirm signal absence .
-
Cross-Reactivity Checks: Test antibody on tissues/cells lacking homologous proteins (e.g., Arabidopsis mutants for plant studies) .
How do I resolve contradictory data between WB and IP results for At1g25270?
Methodological Answer:
-
Epitope Accessibility: WB denatures proteins, exposing linear epitopes, whereas IP relies on native conformation. Perform peptide-blocking assays to confirm epitope identity .
-
Post-Translational Modifications (PTMs): Use phosphatase/protease inhibitors during IP to preserve PTMs that may affect antibody binding .
-
Quantitative Parallel Analysis: Normalize IP input/output ratios to WB signals to identify stoichiometric discrepancies .
Common Pitfalls:
| Issue | WB Result | IP Result | Resolution |
|---|---|---|---|
| Non-linear epitope | Positive | Negative | Use recombinant protein for IP validation |
| PTM-dependent binding | Variable | Consistent | Perform glycan/phospho-specific assays |
What strategies improve reproducibility in multiplex assays using this antibody?
Methodological Answer:
-
Cross-Validation with Fab Fragments: Replace full-length IgG with antigen-binding fragments (Fab) to reduce Fc-mediated non-specific binding in flow cytometry or imaging .
-
Dye-Labeling Efficiency: Quantify fluorophore-to-antibody ratio (F/P ratio) using spectrophotometry; aim for 3–6 dyes per IgG to avoid quenching .
-
Lot-to-Lot Normalization: Pre-test multiple antibody lots under identical conditions and standardize using a reference lysate .
How can I map the epitope recognized by the At1g25270 antibody?
Methodological Answer:
-
Phage Display Libraries: Screen peptide libraries to identify binding motifs .
-
Alanine Scanning Mutagenesis: Express truncated/mutated recombinant At1g25270 variants in HEK293 cells and test antibody reactivity .
-
Structural Prediction Tools: Use AlphaFold-predicted epitopes to guide experimental validation .
Example Epitope Mapping Workflow:
-
Express overlapping 15-mer peptides covering At1g25270.
-
Perform dot-blot assays with the antibody.
Data Contradiction Analysis Framework
For conflicting results across studies:
-
Antibody Clonality: Monoclonal vs. polyclonal antibodies exhibit distinct cross-reactivity profiles .
-
Species-Specificity: Validate antibody reactivity in the model organism used (e.g., Arabidopsis vs. heterologous systems) .
-
Application-Specific Context: Antibody performance in WB does not guarantee functionality in IF or IP .
